Custo-efetividade de Alentuzumabe vs. Natalizumabe no tratamento de terceira linha da esclerose múltipla remitente recorrente para a saúde suplementar no Brasil

Autor: Jessica Nacazume, Henrique Cavalcanti, Guilherme Julian, André F. Ballalai, Erico Carmo, Priscila Bueno, Roberta Monteiro

Publikováno v: Jornal de Assistência Farmacêutica e Farmacoeconomia, Vol 3, Iss 4 (2022)

Objetivo: A esclerose múltipla é uma doença crônica, inflamatória e degenerativa do sistema nervoso central que afeta aproximadamente 2,5 milhões de pessoas no mundo. Cerca de 80% dos casos são classificados no fenótipo ‘remitente recorrent

Externí odkaz: https://doaj.org/article/0edc22fab9e84b9f809b377a4b229be0

Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers

Autor: Enedina Maria Lobato de Oliveira, Renata Faria Simm, Gorana Dasic, Marília Mamprim de Morais, Samira Luiza dos Apostolos Perreira, Dagoberto Callegaro

Publikováno v: Arquivos de Neuro-Psiquiatria, Vol 73, Iss 9, Pp 736-740 (2015)

Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We

Externí odkaz: https://doaj.org/article/e06136b97d094b039fe615a4b6f35b22

[Untitled]

Autor: Yára Dadalti Fragoso, Soniza Vieira Alves-Leon, Walter Oleschko Arruda, Margarete de Jesus Carvalho, Elizabeth Regina Comini-Frota, Éber Castro Corrêa, Maria Lucia Brito Ferreira, Paulo Diniz da Gama, Sidney Gomes, Marcus Vinicius Magno Gonçalves, Damacio Ramón Kaimen-Maciel, Maria Fernanda Mendes, Rogerio Rizo Morales, Andre Muniz, Pedro Rippel Salgado, Heloisa Helena Ruocco, Livia Brito Bezerra de Albuquerque, Joseph Bruno Bidin Brooks, Letícia Fêzer, Sergio Georgetto, Josiane Lopes, Fabíola Rachid Malfetano, Isabella D'Andrea Meira, Celso Luis Silva Oliveira, Francisco Tomaz Meneses de Oliveira, Fabiana Safanelli, Massaco Satomi

Publikováno v: Arquivos de Neuro-Psiquiatria, Vol 71, Iss 3, Pp 137-141 (2013)

Objective To assess the prevalence and the profile of adverse events (AE) of natalizumab in patients with multiple sclerosis (MS). Methods Data collection from neurologists attending to patients with MS at specialized units in Bra

Externí odkaz: https://doaj.org/article/066c2247473b4a5b8af6ac9f4fa33e26

Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive

Autor: Yara Dadalti Fragoso, Maria Fernanda Mendes, Walter Oleschko Arruda, Jefferson Becker, Joseph Bruno Bidin Brooks, Margarete de Jesus Carvalho, Elizabeth Regina Comini-Frota, Renan Barros Domingues, Maria Lucia Brito Ferreira, Alessandro Finkelsztejn, Paulo Diniz da Gama, Sidney Gomes, Marcus Vinicius Magno Goncalves, Damacio Ramon Kaimen-Maciel, Rogerio de Rizo Morales, Andre Muniz, Heloisa Helena Ruocco, Pedro Rippel Salgado, Livia Brito Bezerra de Albuquerque, Rodrigo Assad Diniz da Gama, Sergio Georgeto, Josiane Lopes, Celso Luis Silva Oliveira, Francisco Tomaz Meneses Oliveira, Juliana Safanelli, Patricia Correia de Oliveira Saldanha, Massaco Satomi

Publikováno v: Arquivos de Neuro-Psiquiatria, Vol 71, Iss 10, Pp 780-782 (2013)

Objective Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) in

Externí odkaz: https://doaj.org/article/73c6cb87d7fb4cada41a3d8bb0d36c6a

Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients

Autor: Augusto César Penalva de Oliveira, Lenira Moraes, Luiz Henrique da Silva Nali, Dagoberto Callegaro, Camila Malta Romano, Maria Cristina Domingues da Silva Fink

Publikováno v: Arquivos de Neuro-Psiquiatria, Vol 72, Iss 12, Pp 960-965 (2014)
Arquivos de Neuro-Psiquiatria v.72 n.12 2014
Arquivos de neuro-psiquiatria
Academia Brasileira de Neurologia
instacron:ABNEURO
Arquivos de Neuro-Psiquiatria, Volume: 72, Issue: 12, Pages: 960-965, Published: 02 DEC 2014

Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis who have failed traditional prior therapies. However, prolonged use, prior immunosuppressive therapy and anti-JCV antibody status have been associated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc54ce6a28d58e1f6c904f7e77a00419
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2014001200960&lng=en&tlng=en